In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer

Soulaimane Aboulouard; Maxence Wisztorski; Marie Duhamel; Philippe Saudemont; Tristan Cardon; Fabrice Narducci; Anne-Sophie Lemaire; Firas Kobeissy; Eric Leblanc; Isabelle Fournier; Michel Salzet

doi:10.1016/j.xcrm.2021.100318

In-depth proteomics analysis of sentinel lymph nodes from individuals with endometrial cancer

Cell Rep Med. 2021 Jun 15;2(6):100318. doi: 10.1016/j.xcrm.2021.100318.

Authors

Affiliations

¹ Université Lille, INSERM, CHU Lille, U1192, Laboratoire Protéomique, Réponse Inflammatoire et Spectrométrie de Masse (PRISM), 59000 Lille, France.
² Department of Gynecology Oncology, Oscar Lambret Center, 59000 Lille, France.
³ Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.

Abstract

Endometrial cancer (EC) is one of the most common gynecological cancers worldwide. Sentinel lymph node (SLN) status could be a major prognostic factor in evaluation of EC, but several prospective studies need to be performed. Here we report an in-depth proteomics analysis showing significant variations in the SLN protein landscape in EC. We show that SLNs are correlated to each tumor grade, which strengthens evidence of SLN involvement in EC. A few proteins are overexpressed specifically at each EC tumor grade and in the corresponding SLN. These proteins, which are significantly variable in both locations, should be considered potential markers of overall survival. Five major proteins for EC and SLN (PRSS3, PTX3, ASS1, ALDH2, and ANXA1) were identified in large-scale proteomics and validated by immunohistochemistry. This study improves stratification and diagnosis of individuals with EC as a result of proteomics profiling of SLNs.

Trial registration: ClinicalTrials.gov NCT02598219.

Keywords: alternative proteins; diagnosis; endometrial cancer; ghost proteome; protein mutations; proteomics; sentinel lymph nodes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aldehyde Dehydrogenase, Mitochondrial / genetics*
Aldehyde Dehydrogenase, Mitochondrial / metabolism
Amino Acid Sequence
Annexin A1 / genetics*
Annexin A1 / metabolism
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
C-Reactive Protein / genetics*
C-Reactive Protein / metabolism
Endometrial Neoplasms / diagnosis
Endometrial Neoplasms / genetics*
Endometrial Neoplasms / mortality
Endometrial Neoplasms / pathology
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Lymph Node Excision / methods
Lymphatic Metastasis
Neoplasm Grading
Prognosis
Prospective Studies
Proteomics / methods
Sentinel Lymph Node / metabolism*
Sentinel Lymph Node / pathology
Sentinel Lymph Node / surgery
Sentinel Lymph Node Biopsy / methods
Serum Amyloid P-Component / genetics*
Serum Amyloid P-Component / metabolism
Signal Transduction
Survival Analysis
Trypsin / genetics*
Trypsin / metabolism

Substances

ANXA1 protein, human
Annexin A1
Biomarkers, Tumor
Serum Amyloid P-Component
PTX3 protein
C-Reactive Protein
ALDH2 protein, human
Aldehyde Dehydrogenase, Mitochondrial
PRSS3 protein, human
Trypsin

Associated data

ClinicalTrials.gov/NCT02598219